Hanmi Pharm. Co. | Date: 2015-11-06
Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (
Hanmi Pharm. Co. | Date: 2014-02-26
The present invention relates to an insulin analog that has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin, a conjugate prepared by linking the insulin analog and a carrier, a long-acting formulation including the conjugate, and a method for preparing the conjugate.
Hanmi Pharm. Co. | Date: 2014-03-05
Provided is a method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond. The method for efficiently preparing the physiologically active polypeptide conjugate uses a salt in a coupling reaction to solve the problem of low production yield during preparation of the physiologically active polypeptide conjugate. The conjugate of physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region can be produced with high purity and yield by the subject method. Due to the method for preparing the physiologically active polypeptide conjugate, production costs can be reduced. Therefore, the method can be used to develop long-acting formulations of physiologically active polypeptides, which have improved industrial applicability and drug regulation compliance.
Hanmi Pharm. Co. | Date: 2015-06-22
Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
Hanmi Pharm. Co. | Date: 2014-02-03
The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into